CSIMarket Company Name, Ticker, Customers, else..
 
Heron Therapeutics Inc   (HRTX)
Other Ticker:  
 
 
Price: $0.9909 $-0.01 -0.910%
Day's High: $1.02 Week Perf: -8.25 %
Day's Low: $ 0.98 30 Day Perf: -40.66 %
Volume (M): 1,276 52 Wk High: $ 4.68
Volume (M$): $ 1,264 52 Wk Avg: $2.26
Open: $1.01 52 Wk Low: $0.95



 Market Capitalization (Millions $) 119
 Shares Outstanding (Millions) 120
 Employees 336
 Revenues (TTM) (Millions $) 118
 Net Income (TTM) (Millions $) -137
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 1

Heron Therapeutics Inc
Heron Therapeutics Inc. is a pharmaceutical company that is focused on the development and commercialization of innovative therapies to address unmet medical needs. The company is dedicated to providing patients with safe and effective alternatives to existing treatments that do not adequately address their conditions or that may be associated with undesirable side effects.

Heron Therapeutics was founded in 1983 and is based in San Diego, California. The company operates under the leadership of CEO Barry Quart, who has been with the company since 2000. The company has a team of over 300 employees who work tirelessly to develop new and innovative treatments that improve patient outcomes.

Heron Therapeutics has developed a proprietary drug delivery system called Sustained Release (SR) technology, which is used to develop long-acting formulations of existing drugs. The technology allows for drugs to be released over an extended period, which can eliminate the need for multiple dosing throughout the day. SR technology has been used to develop numerous products in the Heron pipeline, including Zynrelef (bupivacaine and meloxicam), a recently FDA-approved drug for postoperative pain management.

Heron Therapeutics focuses on developing products for pain management, cancer supportive care, and rare diseases. The company's lead product candidate, HTX-011, is a novel local anesthetic that is being developed for postoperative pain management. The drug, which is administered during surgery, has been shown to provide superior pain relief compared to existing therapies and may reduce the need for opioids to manage postoperative pain.

In addition to its research and development efforts, Heron Therapeutics has a focus on commercialization. The company has a dedicated sales and marketing team that is responsible for launching new products and promoting existing products to healthcare professionals.

Overall, Heron Therapeutics is a biotechnology company that is dedicated to advancing medical treatments for unmet medical needs. With a focus on innovation, research and development, and commercialization, the company is well-positioned for continued growth and success in the industry.


   Company Address: 4242 Campus Point Court San Diego 92121 CA
   Company Phone Number: 251-4400   Stock Exchange / Ticker: NASDAQ HRTX
   HRTX is expected to report next financial results on November 07, 2023.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Ibio Inc

Ibio Inc's Fourth Quarter Earnings Show Alarming Surge in Losses and Share Value Decline



In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.
Mei Pharma Inc

A Surprising Twist in the Fourth Quarter of 2023


Date: November 15, 2023
Mei Pharma Inc, a leading pharmaceutical company, has experienced a significant turnaround in their financial performance during the financial fourth quarter of 2023, with a reduction in losses per share and improved earnings per share. However, the company witnessed a sharp decline in revenue compared to the previous year, mainly attributed to slowing demand and other market factors.
During the financial fourth quarter of 2023, Mei Pharma Inc reduced their loss per share from $-0.13 a year ago to $-0.08 per share, indicating a 38.46% improvement. Furthermore, earnings per share showed a significant improvement from $-2.32 per share in the preceding quarter to the current figure. These positive numbers highlight the company's ability to manage their expenses effectively and generate better returns for their shareholders.
Cannapharmarx Inc

Cannapharmarx Inc. Shows Promising Results with Reduced Losses and Growing Revenue in First Quarter of 2023



The first quarter of 2023 has shown significant promise for Cannapharmarx Inc, a major player in the pharmaceutical preparations industry. While the company has not revealed any top-line figures yet, industry observers are examining the operating shortfall of $-0.720277 million, shedding light on the positive performance of the firm during this period. By comparing it to previous quarters and assessing other growth indicators, we can anticipate a bullish outlook for Cannapharmarx Inc in the near future.
Reduced Losses and Growing Revenue:
In the first quarter of 2022, Cannapharmarx Inc experienced an operating shortfall of $-0.715558 million. However, with effective cost-cutting measures and revenue growth strategies, the company has managed to improve its financial performance in Q1 2023. The company's losses of $-2.072 million in the first quarter of 2022 have been reduced to $-1.413 million, showcasing a significant improvement in their bottom line. This reduction of losses is indicative of a more efficient and profitable operation.
Benitec Biopharma Inc

Benitec Biopharma Inc Revolutionizes the Biotech Industry with Remarkable Q2 2023 Financial Performance!

Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.
Kintara Therapeutics Inc

Kintara Therapeutics Inc Faces Challenging Times as Fourth Quarter Earnings Plunge, Sparking Investor Worries

Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.





 

Heron Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com